There are to date no objective clinical laboratory blood tests for psychotic disease states. We provide proof of principle for a convergent functional genomics (CFG) approach to help identify and prioritize blood biomarkers for two key psychotic symptoms, one sensory (hallucinations) and one cognitive (delusions). We used gene expression profiling in whole blood samples from patients with schizophrenia and related disorders, with phenotypic information collected at the time of blood draw, then cross-matched the data with other human and animal model lines of evidence. Topping our list of candidate blood biomarkers for hallucinations, we have four genes decreased in expression in high hallucinations states (Fn1, Rhobtb3, Aldh1l1, Mpp3), and three genes increased in high hallucinations states (Arhgef9, Phlda1, S100a6). All of these genes have prior evidence of differential expression in schizophrenia patients. At the top of our list of candidate blood biomarkers for delusions, we have 15 genes decreased in expression in high delusions states (such as Drd2, Apoe, Scamp1, Fn1, Idh1, Aldh1l1), and 16 genes increased in high delusions states (such as Nrg1, Egr1, Pvalb, Dctn1, Nmt1, Tob2). Twenty-five of these genes have prior evidence of differential expression in schizophrenia patients. Predictive scores, based on panels of top candidate biomarkers, show good sensitivity and negative predictive value for detecting high psychosis states in the original cohort as well as in three additional cohorts. These results have implications for the development of objective laboratory tests to measure illness severity and response to treatment in devastating disorders such as schizophrenia.
Introduction
Our group has developed a powerful combined approach for extracting signal from noise in genetic and gene expression studies, termed convergent functional genomics (CFG). CFG translationally integrates multiple independent lines of evidencegenetic and functional genomic data, from human studies and animal models, as a Bayesian strategy for identifying and prioritizing findings, reducing the false-positives and false-negatives inherent in each individual approach. The CFG methodology has already been applied with some success to help identify and prioritize candidate genes, pathways and mechanisms for neuropsychiatric disorders such as bipolar disorder, 1,2 alcoholism 3 and schizophrenia, 4 as well as blood biomarker discovery for mood disorders. 5 We have now applied this approach (Figures 1 and 2 ) to blood biomarker discovery efforts for hallucinations and delusions, core symptoms of psychotic disorders. Objective blood biomarkers for illness state and treatment response would make a significant difference in our ability to assess and treat patients with psychotic disorders, eliminating subjectivity and reliance on patient's self-report of symptoms.
Materials and methods

Human subjects
We present data from four cohorts ( Table 1) . One cohort consisted of 31 subjects with psychotic disorders (schizophrenia, schizoaffective disorder and substance-induced psychosis), from which the primary biomarker data was derived, from testing done at their first visit (v1). A second cohort consisted of 17 subjects from the first cohort that had a change in psychotic symptom (hallucinations or delusions) Positive and Negative Symptom Scale (PANSS) scores at follow-up testing 3 months (v2) or 6 months (v3) later. A third cohort consisted of 10 new subjects with psychotic disorders, and the fourth cohort consisted of 9 subjects from the third cohort that had a change in symptom scores at follow-up testing 3 months (v2) later.
Subjects consisted primarily of men (and one woman) over 18 years of age. Subjects were recruited from the patient population at the Indianapolis VA Medical Center and the Indiana University School of Medicine. A demographic breakdown is shown in Table 1 . We focused in our initial studies primarily on an age-matched male population, due to the demographics of our catchment area (primarily male in a VA Medical Center), and to minimize any potential gender-related state effects on gene expression, which would have decreased the discriminative power of our analysis given our relatively small sample size. The subjects were recruited largely through referrals from care providers, the use of brochures left in plain sight in public places and mental health clinics, and through word of mouth. Subjects were excluded if they had significant acute medical or neurological illnesses, or had evidence of active substance abuse or dependence. All subjects understood and signed informed consent forms detailing the research goals, procedure, caveats and safeguards. Subjects completed diagnostic assessments by an extensive structured clinical interview-Diagnostic Interview for Genetic Studies-at a baseline visit, followed by up to three testing visits, each three months apart. At each testing visit, they received a psychosis rating scale (PANSS), which includes items that score symptoms of hallucinations and delusions (see Table 2 ), and blood was drawn. Whole blood (10 ml) African American  3  4  phchp005v2  SZA  45  Male  Caucasian  2  2  phchp006v2  SZA  52  Male  African American  1  1  phchp010v3  SZA  45  Male  Caucasian  1  1  phchp012v2  SZA  55  Male  Caucasian  5  4  phchp013v3  SZA  54  Male  African American  5  4  phchp016v3  SZ  54  Male  African American  4  4  phchp021v3  SZA  49  Male  Hispanic  5  4  phchp022v2  SZ  48  Male  Caucasian  1  1  phchp026v3  SZA  49  Male  African American  1  1  phchp038v3  SZA  59  Male  African American  1  1  phchp040v2  SZA  50  Male  Caucasian  2  5  phchp042v2  SZA  43  Male  Caucasian  3  2  phchp046v2  SZA  45  Male  Caucasian  3  1  phchp047v2  SZA  57  Male  African American  5  5  phchp048v2  SZA  57  Male  African American  1  1  phchp062v2  SZ  56  Male  Caucasian  3  3 Cohort 3: Second psychosis cohort (n = 10) phchp017v2 SZA 53  Male  African American  1  1  phchp058v1  SZ  56  Male  African American  1  1  phchp065v1  SZA  62  Male  Caucasian  2  5  phchp068v1  SZA  57  Male  African American  4  3  phchp069v1  SZ  47  Male  Caucasian  4  5  phchp072v1  SZA  60  Male  Caucasian  2  3  phchp073v1  SZA  50  Male  Caucasian  5  4 was collected in two RNA-stabilizing PAXgene tubes, labeled with an anonymized ID number, and stored at À80 1C in a locked freezer until the time of future processing. Whole blood (predominantly lymphocyte) RNA was extracted for microarray gene expression studies from the PAXgene tubes blood, as detailed below.
Human blood gene expression experiments and analysis RNA extraction. 2.5-5 ml of whole blood was collected into each PAXgene tube by routine venipuncture. PAXgene tubes contain proprietary reagents for the stabilization of RNA. The cells from whole blood were concentrated by centrifugation, the pellet washed, resuspended and incubated in buffers containing Proteinase K for protein digestion. A second centrifugation step was done to remove residual cell debris. After the addition of ethanol for an optimal binding condition the lysate was applied to a silica-gel membrane/column. The RNA bound to the membrane as the column was centrifuged and contaminants were removed in three wash steps. The RNA was then eluted using diethylpyrocarbonatetreated water.
Globin reduction. To remove globin messenger RNA (mRNA), total RNA from whole blood was mixed with a biotinylated Capture Oligo Mix that is specific for human globin mRNA. The mixture was then incubated for 15 min to allow the biotinylated oligonucleotides to hybridize with the globin mRNA. Streptavidin magnetic beads were then added, and the mixture was incubated for 30 min. During this incubation, streptavidin binds the biotinylated oligonucleotides, thereby capturing the globin mRNA on the magnetic beads. The streptavidin magnetic beads were then pulled to the side of the tube with a magnet, and the RNA, depleted of the globin mRNA, was transferred to a fresh tube. The treated RNA was further purified using a rapid magnetic beadbased purification method. This consists of adding an RNA binding bead suspension to the samples, and using magnetic capture to wash and elute the GLOBINclear RNA.
Sample labeling. Sample labeling was performed using the Ambion MessageAmp II-BiotinEnhanced amplified RNA (aRNA) amplification (Ambion Inc., Austin, TX, USA). The procedure is briefly outlined below and involves the following steps:
1. Reverse transcription to synthesize first strand complementary DNA (cDNA) is primed with the T7 Oligo(dT) Primer to synthesize cDNA containing a T7 promoter sequence. 
Analysis
We have used the subject's psychosis scores at time of blood collection, specifically the scores for hallucinations (from 1-no symptoms to 7-extreme symptoms) and the scores for delusions (1-7), obtained from a PANSS scale (Table 2) . We looked only at all or nothing gene expression differences that are identified by Absent (A) vs Present (P) Calls in the Affymetrix MAS software. We classified genes whose expression is detected as Absent in the asymptomatic subjects (no hallucinations or no delusions, scores of 1) and detected as Present in the highly symptomatic subjects (high hallucinations or high delusions, scores of 4 and above), as being candidate biomarker genes for high hallucinations or high delusions states, respectively. Conversely, genes whose expression are detected as Present in the asymptomatic subjects and Absent in the highly symptomatic subjects are being classified as candidate biomarker genes for no hallucinations or no delusions states, respectively.
We employed two thresholds for analysis of gene expression differences between no symptoms and high symptoms (Table 3) . First we used a high threshold, with at least 75% of subjects in the cohort showing a change in expression from Absent to Present between no symptoms and high symptoms (reflecting an at least threefold psychosis state related enrichment of the genes thus filtered). We also used a low threshold, with at least 60% of subjects in the cohort showing a change in expression from Absent to Present between no symptoms and high symptoms (reflecting an at least 1.5-fold psychosis state related enrichment of the genes thus filtered).
The higher threshold would identify candidate biomarker genes that are more common for all subjects, with a lower risk of false positives, whereas the lower threshold will identify genes that are present in more restricted subgroups of subjects, with a lower risk of false negatives. The high threshold candidate biomarker genes have, as an advantage, a higher degree of reliability, as they are present in at least 75% of all subjects with a certain hallucinations state (high symptoms or no symptoms) tested. They may reflect common aspects related to psychosis across a diverse subject population, but may also be a reflection of the effects of common medications used in the population tested, such as antipsychotics. The low threshold genes may have lower reliability, being present in at least 60% of the subject population Table 3 High-and low-threshold analyses in the primary psychosis cohort (n = 31)
Thresholds
Hallucination analyses (12 no hallucinations and 11 high hallucinations)
Delusion analyses (9 no delusions and 13 high delusions)
High-threshold candidate biomarker genes (changed in X 75% subjects; that is, at least 3-fold enrichment)
9/12 no hallucinations vs 9/11 high hallucinations A/P and P/A analysis 7/9 no delusions vs 10/13 high delusions A/P and P/A analysis Low-threshold candidate biomarker genes (changed in X 60% subjects; that is, at least 1.5-fold enrichment)
8/12 no hallucinations vs 7/11 high hallucinations A/P and P/A analysis 6/9 no delusions vs 8/13 high delusions A/P and P/A analysis Genes are considered candidate biomarkers for high hallucinations or high delusions if they are called by the Affymetrix MAS5 software as absent (A) in the blood of no hallucination or, no delusion subjects, and detected as present (P) in the blood of high hallucination or high delusion subjects. Conversely, genes are considered candidate biomarkers for no hallucinations or no delusions if they are detected as present (P) in no hallucination or no delusion subjects and absent (A) in high hallucination or high delusion subjects.
tested, but may capture more of the diversity of genes and biological mechanisms present in a genetically diverse human subject population.
Animal model gene expression studies Our schizophrenia pharmacogenomic model consists of phencyclidine (PCP) and clozapine treatments in mice (see Le-Niculescu et al. 4 for experimental details and analysis/categorization of brain gene expression data).
For the current work, we repeated that series of experiments, to obtain blood gene expression data. All experiments were performed with male C57/BL6 mice, 8-12 weeks of age, obtained from Jackson Laboratories (Bar Harbor, ME, USA), and acclimated for at least 2 weeks in our animal facility prior to any experimental manipulation.
Mice were treated by intraperitoneal injection with single-dose saline, PCP (7.5 mg kg ). Three independent de novo biological experiments were performed at different times. Each experiment consisted of three mice per treatment condition, for a total of nine mice per condition across the three experiments.
Mouse blood collection. Twenty-four hours after drug administration, following behavioral testing, the mice were decapitated to harvest blood. The headless mouse body was put over a glass funnel coated with heparin and approximately 1 ml of blood/mouse was collected into a PAXgene blood RNA collection tubes (Qiagen/BD Diagnostics, Valencia, CA, USA). Blood samples from three mice per treatment condition were pooled. The PAXgene blood vials were stored in À4 1C overnight, and then at À80 1C until future processing for RNA extraction.
RNA extraction and microarray work. For the whole mouse blood RNA extraction, PAXgene blood RNA extraction kit (PreAnalytiX, a Qiagen/BD Company) was used, followed by GLOBINclear-Mouse/Rat (Ambion Inc.) to remove the globin mRNA. All the methods and procedures were carried out as per manufacturer's instructions. The quality of the total RNA was confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). The quantity and quality of total RNA was also independently assessed by 260 nm ultraviolet absorption and by 260/280 ratios, respectively with a Nanodrop spectrophotometer (Thermo Scientific, Wilmington, DE, USA). Starting material of total RNA labeling reactions was kept consistent within each independent microarray experiment. Equal amounts of total RNA extracted from pooled blood samples was used for labeling and microarray assays. We used Mouse Genome 430 2.0 arrays (Affymetrix). The GeneChip Mouse Genome 430 2.0 Array contain over 45 000 probe sets that analyze the expression level of transcripts and variants from over 34 000 well-characterized mouse genes. Standard Affymetrix protocols were used to reverse transcribe the mRNA and generate biotinlylate cRNA (http:// www.affymetrix.com/support/downloads/manuals/ expression_s2_manual.pdf). The amount of cRNA used to prepare the hybridization cocktail was kept constant intra-experiment. Samples were hybridized at 45 1C for 17 h under constant rotation. Arrays were washed and stained using the Affymetrix Fluidics Station 400 and scanned using the Affymetrix Model 3000 Scanner controlled by GCOS software. All sample labeling, hybridization, staining and scanning procedures were carried out as per manufacturer's recommendations. All arrays were scaled to a target intensity of 1000 using Affymetrix MASv 5.0 array analysis software. Quality control measures including 3 0 /5 0 ratios for glyceraldehyde 3-phosphate dehydrogenase and b-actin, scaling factors, background, and Q values were within acceptable limits.
Microarray data analysis. Data analysis was performed using Affymetrix Microarray Suite 5.0 software (MAS v5.0). Default settings were used to define transcripts as present (P), marginal (M) or absent (A). A comparison analysis was performed for each drug treatment, using its corresponding saline treatment as the baseline. 'Signal,' 'Detection,' 'Signal Log Ratio,' 'Change' and 'Change P-value' were obtained from this analysis. Only transcripts that were called Present in at least one of the two samples (saline or drug) intra-experiment, and that were reproducibly changed in the same direction in at least two out of three independent experiments, were analyzed further.
Cross-validation and integration: CFG Gene identification. The identities of transcripts were established using NetAffx (Affymetrix), and confirmed by cross-checking the target mRNA sequences that had been used for probe design in the Mouse Genome 430 2.0 Array GeneChip or the Affymetrix Human Genome U133 Plus 2.0 GeneChip with the GenBank database. Where possible, identities of ESTs were established by BLAST searches of the nucleotide database. A National Center for Biotechnology Information (NCBI) (Bethesda, MD, USA) BLAST analysis of the accession number of each probe-set was done to identify each gene name. BLAST analysis identified the closest known gene existing in the database (the highest known gene at the top of the BLAST list of homologues) which then could be used to search the GeneCards database (Weizmann Institute, Rehovot, Israel). Probe sets that did not have a known gene were labeled 'EST' and their accession numbers kept as identifiers.
Human postmortem brain convergence. Information about our candidate genes was obtained using GeneCards, the Online Mendelian Inheritance of Man database (http://ncbi.nlm.nih.gov/entrez/query. fcgi?db = OMIM), as well as database searches using PubMed (http://ncbi.nlm.nih.gov/PubMed) and various combinations of keywords (gene name, psychosis, schizophrenia, schizoaffective, human, brain, postmortem). Postmortem convergence was deemed to occur for a gene if there were published reports of human postmortem data showing changes in expression of that gene in brains from patients with psychotic disorders (schizophrenia, schizoaffective d/o). In terms of concordance of direction of change in expression between published postmortem brain data and our human blood data, we made the assumption that schizophrenia postmortem brain data reflected a highly symptomatic phase of the illness. While this may arguably be the case, it is nevertheless an assumption, as no consistent objective data exists regarding the phase of the illness when the subjects deceased, which is one of the limitations of human postmortem brain data to date.
Human genetic data convergence. To designate convergence for a particular gene, the gene had to have published positive reports from candidate gene association studies, or map within 10 cM of a microsatellite marker for which at least one published study showed evidence for genetic linkage to psychotic disorders (schizophrenia or schizoaffective disorder). The University of Southampton's sequence-based integrated map of the human genome (The Genetic Epidemiological Group, Human Genetics Division, University of Southampton: http://cedar.genetics.soton.ac.uk/public_ html/) was used to obtain cM locations for both genes and markers. The sex-averaged cM value was calculated and used to determine convergence to a particular marker. For markers that were not present in the Southampton database, the Marshfield database (Center for Medical Genetics, Marshfield, WI, USA: http://research.marshfieldclinic.org/genetics) was used with the NCBI Map Viewer web-site to evaluate linkage convergence.
CFG analysis scoring. Genes were given the maximum score of 2 points if changed in our human blood samples with high threshold analysis, and only 1 point if changed with low threshold (see Figure 1) . They received 1 point for each external crossvalidating line of evidence: other human tissue data, human genetic data (1 point for assoc., 0.5 point for linkage), animal model brain data, and animal model blood data. Genes received additional bonus points if changed in other human tissue and our blood data, as follows: for brain-2 points if changed in the same direction, 1 point if changed in opposite direction; for lymphoblastoid cell lines and fibroblasts, 1 point if changed in same direction, 0.5 point if changed in opposite directions. Genes also received additional bonus points if changed in brain and blood of the animal model, as follows: 1 point if changed in the same direction in the brain and blood, and 0.5 points if changed in opposite direction. Thus the total maximum CFG score that a candidate biomarker gene can have is 9 (2 þ 4 þ 2 þ 1). As we are interested in discovering blood biomarkers, and because of caveats discussed above, we weighted more heavily our own live subject human blood data (if it made the high threshold cut) than literaturederived human postmortem brain data, human genetic data, or our own animal model data. We also weighted more heavily the human blood-brain concordance than the animal model blood-brain concordance. Other ways of weighing the scores of line of evidence may give slightly different results in terms of prioritization, if not in terms of the list of genes per se. Nevertheless, we feel that this empirical scoring system provides a good separation of genes based on our focus on identifying human blood candidate biomarkers.
Pathway analysis. Ingenuity Pathway Analysis 7.0 (Ingenuity Systems, Redwood City, CA, USA) was used to analyze the biological roles (molecular and cellular functions) categories of the top candidate genes resulting from our CFG analysis.
Results
Hallucinations biomarkers
Using our approach, out of over 40 000 genes and ESTs on the Affymetrix Human Genome U133 Plus 2.0 GeneChip, we have ended up with 50 candidate biomarker genes (Supplementary Table S1 ) which had a CFG score of 2 or above, meaning either maximal score from the A/P analysis or at least one other line of prior independent evidence for potential involvement in psychotic disorders. Of interest, one of our candidate biomarker genes (Phlda1 6 ) had been previously reported to be changed in expression in the same direction, in lymphoblastoid cell lines from schizophrenia subjects. Another one, Adrbk2 (adrenergic receptor kinase, beta 2), also known as Grk3, has been previously reported by us to be decreased at a protein level in lymphoblastoid cell lines from bipolar patients. 1 Selecting the top CFG scoring candidate biomarkers for hallucinations (CFG score of 3 and above, meaning, for example, a maximal score from the A/P analysis and at least one other line of prior independent evidence for potential involvement in psychotic disorders), we generated a panel of seven biomarkers for hallucinations (Table 4) . To test the predictive value of our panel (to be called the BioM-7 hallucinations panel), we have looked in the cohort of 31 psychotic disorders subjects, containing the 23 subjects (12 no hallucinations, 11 high hallucinations) from which the candidate biomarker data was derived, as well as 8 additional subjects with hallucinations symptoms in the intermediate range (PANSS hallucination scores of 2 or 3). We derived a prediction score for each subject, based on the presence or absence of the biomarkers of the panel in their blood GeneChip data. Each of the biomarkers gets a score of 1 if it is detected as Present (P) in the Table 3S ).
Blood biomarkers for psychosis SM Kurian et al blood from that subject, 0.5 if it is detected as Marginally Present (M), and 0 if it is called Absent (A). The ratio of the average of the high hallucinations biomarker scores divided by the average of the no hallucinations biomarker scores is multiplied by 100, and provides a prediction score. If the ratio of high hallucinations biomarkers to no hallucinations biomarkers is 1, that is, the two sets of genes are equally represented, the prediction score is 1 Â 100 = 100. The higher this score, the higher the predicted likelihood that the subject will have high hallucinations. We then compared the predictive score with actual PANSS hallucination scores. A prediction score of above 100 had an 80% sensitivity and a 70% specificity for predicting high hallucinations (Table 6 ). Additionally, we have also conducted human blood gene expression analysis in three other cohorts, subsequently collected. Cohort 2 consisted of 17 subjects from the first cohort that had a change in psychotic symptom (hallucinations and/or delusions) scores at follow-up testing 3 months (v2) or 6 months (v3) later. Cohort 3 consisted of 10 new subjects with psychotic disorders, and Cohort 4 consisted of 9 subjects from Cohort 3 that had a change in symptom scores at follow-up testing 3 months (v2) later.
These cohorts were used as replication cohorts, to verify the predictive power of the hallucinations state biomarker panel identified by analysis of data from the primary psychosis cohort. Overall, the BioM-7 panel had good sensitivity and negative predictive value for high hallucinations state across the different cohorts ( Figure 3 and Table 6 ). Detecting and not missing patients who have high symptom levels is arguably the critical clinical issue, as well as a potential practical application. As such, the sensitivity of the tests for high symptoms (high hallucinations), as well as its negative predictive value, is the most important parameter in that regard.
Delusions biomarkers
Using our approach, we have identified 107 candidate biomarker genes (Supplementary Table S2 ) which had a CFG score of 2 or above, meaning either maximal score from the A/P analysis or at least one other line of prior independent evidence for potential involvement in psychotic disorders.
Selecting the top CFG scoring candidate biomarkers for delusions (CFG score of 3 and above), we generated a panel of 31 biomarkers (Table 5 ). To test the predictive value of our panel (to be called the BioM-31 delusions panel), we have looked in the cohort of 31 psychotic disorders subjects, containing the 23 subjects (9 no delusions, 13 high delusions) from which the candidate biomarker data was derived, as well as 9 additional subjects with delusions symptoms in the intermediate range (PANSS delusions scores of 2 or 3). We derived a prediction score for each subject, based on the presence or absence of the biomarkers of the panel in their blood GeneChip data. As for hallucinations, each of the biomarkers gets a score of 1 if it is detected as Present (P) in the blood form that subject, 0.5 if it is detected as Marginally Present (M), and 0 if it is called Absent (A). The ratio of the average of the high delusions biomarker scores divided by the average of the no delusions biomarker scores is multiplied by 100, and provides a prediction score. If the ratio of high delusions biomarkers to no delusions biomarkers is 1, that is, the two sets of genes are equally represented, the prediction score is 1 Â 100 = 100. The higher this score, the higher the predicted likelihood that the subject will have high delusions. We then compared the predictive score with actual PANSS delusions scores. A prediction score of above 100 had a 92.3% sensitivity and a 61.1% specificity for predicting high delusions ( Figure 4 and Table 6) .
Additionally, we also tested our BioM-31 delusions panel in the three other cohorts subsequently collected, used as replication cohorts, to verify the predictive power of the delusions state biomarker panel identified by analysis of data from the primary psychosis cohort. Overall, the BioM-31 panel had good sensitivity and negative predictive value for high delusions state, with the exception of one of the cohorts-Cohort 2 (Table 6 ). It may be that delusions are more private, diverse and ambiguous to assess by PANSS than hallucinations. If not asked specifically about a particular delusion, a subject may not endorse it. As some of our PANSS testing was done by testers who were not familiar clinically with the subject (that is, different testers had performed the Diagnostic Interview for Genetic Studies in those subjects), that could potentially have contributed to false negatives on the PANSS scoring for delusions, and as a consequence resulted in the apparent lower sensitivity of our test in Cohort 2. Regardless if that was the case or not, the reluctance of patients to report psychiatric symptoms underscores the necessity of developing objective tests such as the blood biomarker ones described in this paper, and the need to validate them in multiple cohorts.
Discussion
Strengths and limitations of our work As a way of identifying biomarkers, we initially conducted gene expression profiling studies in peripheral whole blood from a primary cohort of 31 human subjects with psychotic disorders (30 males, 1 female) (see Table 1 ). We measured their psychological testing (PANSS) assessed hallucinations scores, respectively delusions scores (on a scale of 1 to 7) at the time of blood collection. We then looked at gene expression differences between the no symptoms of hallucinations, respectively delusions vs high symptoms of hallucinations, respectively delusions, groups. As in our previous work to identify mood biomarkers, 5 we have used an all or nothing Absent (A) vs. Present (P) Calls in the Affymetrix MAS software. A is scored as 0, M as 0.5 and P as 1. BioM Hallucinations Prediction Score is based on the ratio of the sum of the scores for high mood biomarkers and sum of scores for low mood biomarkers, multiplied by 100. We have used a cutoff score of above 100 for high hallucinations. Infinity-denominator is 0. ND-not determined. Table 3S ).
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Given the genetic heterogeneity and variable environmental exposure, it is possible, indeed likely, that not all subjects will show changes in all the biomarker genes. Hence we have used two stringency thresholds: changes in 75% of subjects, and in 60% of subjects with no symptoms vs high symptoms. Moreover, our approach, as described above, is predicated on the existence of multiple cross-validators for each gene that is called a candidate biomarker (Figure 1 ): (1) is it changed in human blood, (2) is it changed in animal model brain, (3) is it changed in animal model blood, (4) is it changed in postmortem human brain, and (5) is there any human genetic data (linkage, association) implicating the gene in psychosis. All these lines of evidence are the result of independent experiments. The virtues of this networked Bayesian approach are that, if one or another of the nodes (lines of evidence) becomes questionable/non-functional upon further evidence in the field, the network is resilient and maintains functionality. The prioritization of candidates is similar conceptually to the Google PageRank algorithm 7 -the more links (lines of evidence) to a candidate, the higher it will come up on our priority list. As more evidence emerges in the field for some of these genes, they will move up in the prioritization scoring. 8 Using such an approach, we were able to identify and focus on a small number of genes as likely candidate biomarkers, out of the over 40 000 transcripts (about half of which are detected as Present in each subject) measured by the microarrays we used.
By cross-validating with other human datasets and with animal model data using CFG (Figure 1 ), we were able to extract a shorter list of genes for which there are external corroborating line of evidence (human genetic evidence, human postmortem brain data, animal model brain and blood data) linking them to psychotic disorders, thus reducing the risk of false positives. This cross-validation identifies candidate biomarkers that are more likely directly related to the relevant disease neuropathology, as opposed to being potential artifactual effects related to a particular cohort or indirect effects of lifestyle and environment. The power of our CFG approach is exemplified in the fact that our biomarker panels had good predictive power in independent cohorts, a key litmus test in our view, and one that needs to be applied more systematically in this nascent field.
All subjects recruited were on prior prescribed medications. We cannot exclude, and in fact would anticipate that medications may have an effect on biomarker expression levels. However, of note, the patients were on a very diverse list of antipsychotics, mood stabilizers, and other psychotropic medications (Supplementary Table S4 ). While that makes pinpointing a particular medication effect not feasible with our current design (clinical trials with specific medications are a better setting for identifying such effects), it is reassuring that we are obtaining with our CFG approach consistent findings that show predictive power in independent cohorts, despite this diversity of medications and of a variety of other environmental effects.
Clozapine, modeled in the pharmacogenomic animal model work, is a broad-spectrum drug, one of the current gold standards, and encompasses many of the actions of some of the other antipsychotics currently used in schizophrenia. The premise of using it, along with PCP, in a pharmacogenomic animal model of schizophrenia, 4 was that they may modulate the expression of genes involved in the pathogenesis of schizophrenia. The findings in that model, crossvalidated with other independent approaches and lines of evidence, support its validity. 4 Comparisons BioM delusions Prediction Score is based on the ratio of the sum of the scores for high mood biomarkers and sum of scores for low mood biomarkers, multiplied by 100. We have used a cutoff score of above 100 for high delusion. Infinity-denominator is 0. ND-not determined.
with the non-medicated normal control group will in the future permit additional distinctions regarding medication effects, as will systematic large-scale within-subject comparisons of subjects whose medications remain constant but symptoms state and markers change from one visit to the next. Moreover, psychosis state and blood gene expression changes may be influenced not only by the presence or absence of medications, but also of drugs of abuse. While we had access to the subject's medical records and clinical information as part of the informed consent for the study, medication noncompliance, on the one hand, and substance abuse, on the other hand, are not infrequent occurrences in psychiatric patients.
More extensive follow-up studies may benefit from the prospective inclusion of toxicology and medication levels testing. That medications and drugs of abuse may have effects on psychosis state and gene expression is in fact being partially modeled in the mouse pharmacogenomic model, with clozapine and PCP treatments respectively. In the end, it is the association of blood biomarkers with psychosis state that has been the primary goal of the work reported in this paper, regardless of the proximal causes, which could be diverse and will need to be the subject of subsequent hypothesis-driven studies beyond the scope of this initial work.
Our sample size for human subjects (n = 31 for the primary cohort; n = 17, n = 10, n = 9 for the other three cohorts) is relatively small, but comparable to the size of cohorts for human postmortem brain gene expression studies. 9, 10, 11 We have in essence studied live donor blood samples instead of postmortem donor brains, with the advantage of better phenotypic characterization, more quantitative state information, and less technical variability. Our approach also permits repeated intra-subject measures when the subject is in different psychosis states, which is an area of future interest and work. In fact, two of our psychosis cohorts are composed of a subset of subjects from the primary and secondary psychosis cohorts, that displayed a different psychosis state (no symptoms vs. intermediate vs. high symptoms) when they were re-tested at a later time point, 3 or 6 months later. Overall, our design was geared towards validating state biomarkers for psychosis while minimizing the noise of genetic and environmental background differences. For trait biomarkers, larger population studies and comparisons with normal controls may be needed. Of note, we have studied almost exclusively male subjects, which means our results might be male-specific. Future studies looking at potential gender differences are warranted.
Overall, our approach of: (1) using individual phenes 12 reflecting internal subjective experiences (hallucinations or delusions), which are the hallmark of psychosis (as opposed to more complex and disease specific state/trait clinical instruments or DSM categorical diagnosis); (2) looking at extremes of state; combined with (3) robust differential expression based on A/P calls, and (4) CFG prioritization, c d Figure 4 Continued. Tables 3S (n = 50 ) and 4S (n = 107).
seems to be able to identify state biomarkers for psychosis that may be, at least in part, generalizable to independent cohorts. In the work reported here, similar to our previously published mood biomarker work, 5 we decided to focus on using CFG scoring as a cut-off to decide which biomarkers to include in panels, rather than find best panel sizes by fit-to-data and receiver operating characteristic curves. We reasoned that an objective CFG scoring cut-off would pick up signal relevant to illness and increase generalizability of our panels across independent cohorts, while a fit-to-data receiver operating characteristic approach, while it might achieve excellent results in the primary cohort, driven at least in part by the noise particular to that cohort, would have poorer results in independent cohorts. In fact, CFG prioritization has been shown to lead to generalizabilty across cohorts not only in our previous 5 and current biomarker work, but also when we applied it to genome-wide association studies data, 13 where P-value criteria are the equivalent of fit-to-data analyses.
While it appears that panels of biomarkers chosen by CFG scoring criteria are the way to go due to population heterogeneity and impact of environmental factors on gene expression, it remains an open empirical question for future work as to how large the panels should be, and whether it may be possible to identify particular single biomarkers that have almost as good a predictive power as that of a larger panel. Ongoing studies are also examining the issue of using incremental differential expression comparisons as opposed to all or nothing A/P calls to identify biomarkers, and are expected to yield an expanded repertoire of biomarkers.
Finally, some of the top candidate biomarker genes identified by our human blood work reported here have no previous evidence for involvement in psychotic disorders other than our mapping them to schizophrenia genetic linkage loci (Supplementary Tables S1 and S2) , and thus constitute novel candidate genes for schizophrenia and related disorders. They merit further exploration in genetic candidate gene association studies, as well as comparison with emerging results from whole-genome association studies of schizophrenia and related disorders. Moreover, as more evidence accumulates in the field, all grist for the mill for our CFG approach, and as prospective studies are done, it is possible that the composition of top biomarker panels for hallucinations and for delusions will be refined or changed for different sub-populations. That being said, it is likely that a large number of the biomarkers that would be of use in different panels and permutations are already present in our lists of candidate biomarker genes (n = 50 for hallucinations- Supplementary  Table S1 ; n = 107 for delusions- Supplementary  Table S2 ).
Hallucinations and delusions: similarities and differences There are more genes with high CFG scores for delusions than for hallucinations, reflecting the fact that more prior evidence exists for them in terms of involvement in schizophrenia and related disorders, and perhaps there is a higher degree of diversity in the genetic architecture of delusions, a more evolved cognitive phene, compared to that of hallucinations, a more primitive sensory phene. As a consequence, using the same CFG cut-off, the panel size for delusions was larger than that for hallucinations. Of note, there is co-directional overlap between the candidate biomarkers for delusions (Supplementary  Table S2 ) and hallucinations (Supplementary Table  S1 ) identified by us, which is reassuring in terms of the technical reliability of our assessments and findings, as these symptoms are often co-morbid clinically. More interestingly, there is some overlap between candidate biomarkers for hallucinations, delusions and mood state previously identified by us 5 (Supplementary Figure S1) , with the mood markers being generally contra-directional to the psychosis markers. Taken together with the heterogeneity of biomarker expression seen in patients that have a similar psychiatric diagnosis (Figures 3 and 4) , our work is consistent with an emerging Lego-like model of complexity, heterogeneity, overlap and interdependence of major psychiatric disorders. 4, 14 Practical implications and predictions of this view would be the relative lack of specificity of single genes and biomarkers for a particular disorder, and the need to use profiling with panels of markers to achieve some disease specificity.
From biomarkers to biology
Remarkably, among our candidate blood biomarker genes for delusions (Table 5 ) are key genes with extensive evidence in brain pathophysiology in psychotic disorders (dopamine receptor 2-Drd2, 15 neuroregulin 1-Nrg1 16, 17 ) and neurodegenerative disorders (apolipoprotein E-ApoE). A polymorphism in Drd2 was reported to be associated specifically with delusions and disorganization symptomatology in major psychoses. 18 Of interest, delusion symptoms were reported to be associated with ApoE epsilon4 allelic variant in late-onset Alzheimer's disease. 19 Moreover, plasma ApoE has been reported to be significantly decreased in treatment-free subjects with schizophrenia spectrum disorders and bipolar disorder, 20 consistent with our findings of ApoE being decreased in expression in high delusion states. Recently, variations in levels of expression of ApoE have also been tied by us to the risk and progression of Alzheimer's disease (AD) irrespective of E4 status. 21 Overall, the ApoE connection warrants future empirical work as a possible molecular underpinning of the Kraepelinian view of schizophrenia as dementia praecox.
At the top of our list of candidate biomarker genes for hallucinations (Table 4) , we have four genes decreased in expression in high hallucinations states (Rhobtb3, Aldh1l1, Mpp3, Fn1), and three genes increased in high hallucinations states (Arhgef9, Phlda1, S100a6). Although all of these genes have prior evidence of differential expression in schizophrenia patients, they are less well known than the candidate biomarker genes for delusions discussed above. A non-obvious top candidate biomarker for hallucinations, increased in high hallucinations state, is Arhgef9 (Cdc42 guanine nucleotide exchange factor 9, also known as collybistin). Arhgef9 can regulate actin cytoskeletal dynamics and may also modulate GABAergic neurotransmission through binding of a scaffolding protein, gephyrin, at the synapse. 22 Interestingly, it has also been implicated in X-linked mental retardation with sensory hyperarousal. 23 Aldh1l1, another non-obvious candidate, is a folate metabolic enzyme with antiproliferative effects, expressed in astrocytes. 24 Fn1 (Fibronectin 1), one of our top scoring candidate biomarkers for hallucinations and for delusions (Figure 2 ), is decreased in high hallucinations states and high delusions states, was also previously reported to be decreased in fibroblasts from schizophrenia patients. 25, 26 It has also been identified as a top candidate gene for alcoholism in previous work from our group. 3 This raises interesting issues about the psychosis-modulating properties of alcohol, specifically hallucinations and delusions symptoms in alcoholism, as well as the more general issue of clinical co-morbidity between schizophrenia and alcoholism.
Overall, the top candidate biomarker genes results discussed above and the results of a biological functions analyses (Tables 6 and 7) suggest that genes involved in cancer, plasticity and connectivity (cell morphology, cell-to-cell signaling and interaction) are prominent players in psychotic disorders, and are reflected in the blood profile, consistent with previous work in the field implicating developmental and connectivity mechanisms in schizophrenia. 4, 27, 28 Unlike for our mood biomarker work, 29 we did not find myelin genes prominently represented among our top psychosis biomarkers. Interestingly, the top canonical pathways for both hallucinations and delusions had to do with interleukin signaling, consistent with previous work in the field implicating immune and inflammatory mechanisms in schizophrenia pathophysiology. 30 For example, IL-8 signaling, which was identified as the top canonical pathway in hallucinations, has been previously implicated as a maternal risk factor for schizophrenia in the offsprings, 31 and IL-8 levels have been reported to be elevated in neuroleptic-free schizophrenia patients compared to normal controls. 32 The model that is emergent is that of increased plasticity and decreased connectivity 4 in high psychosis states compared to no psychosis states. This perspective is of speculative evolutionary interest and pragmatic clinical importance. Speculatively, nature may have selected primitive cellular mechanisms involved in the response to damage, insults and stressors for analogous higher organism level-functions ( Figure 5 ). In this view, psychosis is the higher organismal/brain equivalent of cellular de-differentiation and disconnection such as occurs in early stages of inflammation 33 , tissue re-modeling 34 and cancer metastasis. 35 Specifically, the decrease in FN1 expression and increase in NRG1 expression in high delusions states, as well as decrease in fibronectin expression and increase in calcyclin (S100A6) in high hallucination states, are consistent with increased metastatic potential, though not necessarily increased tumorigenesis/cellular proliferation. Indeed, there seems to be a decrease incidence of respiratory cancers in schizophrenia patients, despite the high incidence of smoking in that population. Pragmatically, the psychotic episodes may be correlated with metastasis in cancers. 36 Typical antipsychotic medications may have protective effects against cancer, 37 consistent also with our connectivity map results identifying fluphenazine as having an opposite gene expression profile to that of high delusions (Table 8) . Lastly, the involvement of interleukin signaling canonical pathways suggests that anti-inflammatory and immune-modulating medications should to be more systematically evaluated for prevention and early intervention in psychotic disorders, consistent with some emerging clinical data. 38, 39 In particular, omega-3 fatty acids may have a favorable effects to side-effects ratio and multiple whole-body health benefits in this patient population. 40 
Conclusions
We propose, and provide proof of principle for, a translational convergent approach to help identify and prioritize blood biomarkers for psychosis states, specifically for hallucinations and for delusions. A validation of our approach is the fact that our primary cohortderived biomarker panels showed not only good sensitivity and specificity in the primary cohort, but also predictive ability in three other cohorts. Finally, a data-derived model for whole-body biological mechanisms associated with psychosis is proposed.
Biomarker-based tests may help with early detection, intervention and prevention efforts in schizophrenia 41, 42 and related disorders, 43 as well as monitoring response to various treatments. In conjunction with other clinical information, such tests may come to play an important part in personalizing treatment to increase precision, effectiveness and avoid adverse reactions. Last but not least, new drug development efforts would particularly benefit from the use of such markers.
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